Previous close | 26.02 |
Open | 26.64 |
Bid | 0.00 x 0 |
Ask | 0.00 x 0 |
Day's range | 26.64 - 26.64 |
52-week range | 25.04 - 32.76 |
Volume | |
Avg. volume | 8,670 |
Market cap | 42.283B |
Beta (5Y monthly) | 0.54 |
PE ratio (TTM) | 45.15 |
EPS (TTM) | 0.59 |
Earnings date | 31 Jul 2024 |
Forward dividend & yield | 1.26 (4.85%) |
Ex-dividend date | 27 Sept 2024 |
1y target est | N/A |
OSAKA, Japan & CAMBRIDGE, Mass., May 14, 2024--Takeda (TSE: 4502/NYSE:TAK) today announced that it will present data from its oncology pipeline and product portfolio at the 60th Annual Meeting of the American Society of Clinical Oncology (ASCO) being held May 31-June 4, 2024, in Chicago, Ill.
OSAKA, Japan & CAMBRIDGE, Mass & LAUSANNE, Switzerland, May 13, 2024--Takeda (TSE:4502/NYSE:TAK) and AC Immune SA (NASDAQ: ACIU) today announced an exclusive, worldwide option and license agreement for AC Immune’s active immunotherapies targeting toxic forms of amyloid beta (Abeta), including ACI-24.060 for the treatment of Alzheimer’s disease.
On Thursday, Japan’s drugmaker Takeda Pharmaceutical Company Limited (NYSE:TAK) announced a restructuring after the company reported a fiscal year 2023 net profit of 144 billion yen (around $954 million), down 54.6% Y/Y. Core net profit fell 12.6% (down 15% at constant currency) to 756.8 billion yen. Takeda said it will incur restructuring costs of about 140 billion yen in fiscal year 2024 as part of a plan to optimize its workforce, cut costs, and strengthen technology. Revenue was 4.26 trillio